Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Br J Haematol. 2024 May;204(5):1577-1578. doi: 10.1111/bjh.19441. Epub 2024 Apr 2.
Defining mechanisms of resistance to hypomethylating agents (HMAs) and biomarkers predictive of treatment response remains challenging in myelodysplastic neoplasm (MDS). Currently available prognostic tools that predict overall survival and transformation to acute myeloid leukaemia have not been powered to predict responses to HMAs. Noguera-Castells et al. comprehensively characterized the epigenomic profile in patients with MDS treated with azacitidine and described a methylation signature-based prognostic tool in predicting responses to azacitidine. Commentary on: Noguera-Castells et al. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: a multicentre retrospective study. Br J Haematol 2024;204:1838-1843.
在骨髓增生异常综合征（MDS）中，确定对低甲基化药物（HMAs）的耐药机制和预测治疗反应的生物标志物仍然具有挑战性。目前可用的预测总生存期和向急性髓系白血病转化的预后工具，还没有预测对 HMAs 反应的能力。Noguera-Castells 等人全面描述了接受阿扎胞苷治疗的 MDS 患者的表观基因组图谱，并描述了一种基于甲基化特征的预测工具，用于预测对阿扎胞苷的反应。述评：Noguera-Castells 等人。阿扎胞苷治疗骨髓增生异常综合征的 DNA 甲基化谱分析和临床反应：一项多中心回顾性研究。英国血液学杂志 2024；204：1838-1843。
